Quantum Capital Management Boosted Olin (OLN) Stake; 7 Bullish Analysts Covering Supernus Pharmaceuticals, Inc. (SUPN)

December 11, 2017 - By Vivian Park

Quantum Capital Management increased Olin Corp (OLN) stake by 22.17% reported in 2017Q2 SEC filing. Quantum Capital Management acquired 43,013 shares as Olin Corp (OLN)’s stock rose 1.10%. The Quantum Capital Management holds 237,063 shares with $7.18M value, up from 194,050 last quarter. Olin Corp now has $5.79B valuation. The stock decreased 1.53% or $0.54 during the last trading session, reaching $34.79. About 1.03 million shares traded. Olin Corporation (NYSE:OLN) has risen 51.90% since December 11, 2016 and is uptrending. It has outperformed by 35.20% the S&P500.

Among 10 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Supernus Pharmaceuticals had 34 analyst reports since August 26, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, July 5 report. The stock has “Hold” rating by Zacks on Wednesday, August 26. The firm has “Market Perform” rating by Northland Capital given on Monday, July 18. FBR Capital initiated Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Wednesday, October 18 with “Buy” rating. The rating was upgraded by Stifel Nicolaus to “Buy” on Wednesday, November 8. The company was maintained on Monday, July 17 by Stifel Nicolaus. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Neutral” rating given on Monday, July 18 by Piper Jaffray. The company was maintained on Monday, November 20 by FBR Capital. As per Tuesday, September 19, the company rating was downgraded by Stifel Nicolaus. The rating was maintained by Stifel Nicolaus with “Hold” on Friday, October 20. See Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) latest ratings:

04/12/2017 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $47 Upgrade
20/11/2017 Broker: FBR Capital Rating: Buy New Target: $50.0 Maintain
08/11/2017 Broker: FBR Capital Rating: Buy New Target: $50.0
08/11/2017 Broker: B. Riley & Co Rating: Buy Old Target: $53 New Target: $50 Maintain
08/11/2017 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Buy Upgrade
06/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0 Maintain
27/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $41.0 Maintain
23/10/2017 Broker: Cowen & Co Rating: Buy New Target: $50.0 Maintain
20/10/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $47.0 Maintain
18/10/2017 Broker: FBR Capital Rating: Buy New Target: $53.0 Initiate

Among 11 analysts covering Olin Corporation (NYSE:OLN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Olin Corporation had 36 analyst reports since August 6, 2015 according to SRatingsIntel. The company was downgraded on Thursday, February 2 by Monness Crespi & Hardt. Longbow downgraded the stock to “Underperform” rating in Wednesday, September 7 report. The rating was maintained by RBC Capital Markets on Tuesday, August 1 with “Buy”. The stock of Olin Corporation (NYSE:OLN) has “Outperform” rating given on Friday, October 30 by RBC Capital Markets. Nomura upgraded the stock to “Buy” rating in Thursday, January 7 report. Susquehanna upgraded the stock to “Positive” rating in Thursday, August 6 report. The rating was maintained by SunTrust on Wednesday, November 1 with “Buy”. Cowen & Co maintained the stock with “Buy” rating in Tuesday, September 5 report. Bank of America initiated it with “Buy” rating and $40 target in Monday, May 8 report. On Tuesday, June 28 the stock rating was upgraded by Cowen & Co to “Outperform”.

Investors sentiment decreased to 0.95 in 2017 Q2. Its down 0.12, from 1.07 in 2017Q1. It dived, as 44 investors sold OLN shares while 91 reduced holdings. 48 funds opened positions while 96 raised stakes. 151.38 million shares or 0.97% less from 152.85 million shares in 2017Q1 were reported. Ameritas Prtnrs holds 49,646 shares. Scopus Asset Lp has invested 0.04% of its portfolio in Olin Corporation (NYSE:OLN). Aureus Asset Llc holds 0.05% or 9,300 shares. Gamco Et Al invested in 0.02% or 125,000 shares. Oarsman Cap Inc holds 1.68% of its portfolio in Olin Corporation (NYSE:OLN) for 121,349 shares. Northwestern Mutual Wealth Mngmt Comm has invested 0% in Olin Corporation (NYSE:OLN). Moreover, Jpmorgan Chase Communication has 0.01% invested in Olin Corporation (NYSE:OLN) for 882,239 shares. Sei Invests reported 247,958 shares stake. Adage Cap Prtnrs Gp Ltd Company stated it has 10.23 million shares. Impala Asset Management Ltd Liability has 1.00 million shares for 1.54% of their portfolio. Prudential invested in 1.30 million shares or 0.06% of the stock. Tiaa Cref Invest Mngmt Limited Co owns 8.04M shares. Fifth Third State Bank owns 38,590 shares. 12,800 are held by Oakbrook Invests Ltd Llc. Us Natl Bank De reported 21,639 shares stake.

The stock increased 1.60% or $0.6 during the last trading session, reaching $38.15. About 227,408 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since December 11, 2016 and is uptrending. It has outperformed by 75.10% the S&P500.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $1.96 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 34.71 P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.